Targeting the Immune Complex–Bound Complement C3d Ligand as a Novel Therapy for Lupus

Abstract excerpt

Abstract Humoral autoimmunity is central to the development of systemic lupus erythematosus (SLE). Complement receptor type 2 (CR2)/CD21 plays a key role in the development of high-affinity Abs and long-lasting memory to foreign Ags. When CR2 is bound by its primary C3 activation fragment–derived ligand, designated C3d, it coassociates with CD19 on B cells to amplify BCR signaling. C3d and CR2 also mediate immune...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Complement system in diseases
• Share to Monoclonal and Polyclonal Antibodies Research
• Share to Systemic Lupus Erythematosus Research